Compounders Research Compare

Gossamer Bio, Inc.(GOSS)

Biotechnology · San Diego, CA

$10.67+0.01 (+0.14%)

Delayed quote: Oct 6, 2026, 3:35 PM EDT

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

San Diego, CA

162 employees

www.gossamerbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Faheem Hasnain

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T19:36:50.380Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:36:50.380Z.

Quote observation: 2026-10-06T19:35:23.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 65,169,378
Total debt · period ending 2026-06-30: 39,103,000
Cash · period ending 2026-06-30: 41,148,000
TTM operating income · period ending 2026-06-30: -166,094,000

FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GOSS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

GOSS Competitors' EV/EBIT Ratio

Gossamer Bio, Inc.

Current

Market Cap

$65.17M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XBiotech Inc.

Market Cap

$66.01M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cingulate Inc.

Market Cap

$66.13M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

iBio, Inc.

Market Cap

$66.24M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alps Group Inc

Market Cap

$63.56M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pliant Therapeutics, Inc.

Market Cap

$63.18M

EV/EBIT Ratio

N/A

TTM Avg

31.50x

3Y Avg

31.50x

5Y Avg

31.50x

InterCure Ltd.

Market Cap

$63.02M

EV/EBIT Ratio

N/A

TTM Avg

9.73x

3Y Avg

23.03x

5Y Avg

21.55x

RenovoRx, Inc.

Market Cap

$62.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Heron Therapeutics, Inc.

Market Cap

$61.97M

EV/EBIT Ratio

N/A

TTM Avg

237.48x

3Y Avg

237.48x

5Y Avg

237.48x

Tiziana Life Sciences Ltd

Market Cap

$68.40M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Gossamer Bio, Inc. (GOSS)	$65.17M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$66.01M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$66.13M	N/A	N/A	N/A	N/A
iBio, Inc. (IBIO)vs ›	$66.24M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$63.56M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.18M	N/A	31.50x	31.50x	31.50x
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	9.73x	23.03x	21.55x
RenovoRx, Inc. (RNXT)vs ›	$62.85M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$61.97M	N/A	237.48x	237.48x	237.48x
Tiziana Life Sciences Ltd (TLSA)vs ›	$68.40M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics